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INTRODUCTION
Although multiple pregnancy rate in natural conception
is less than one percent, this increases significantly in assist-
ed reproductive cycles. The number and rate of multiple
pregnancies have increased over the past two decades, dur-
ing which the number of twin deliveries rose by 65 percent,
and the rate of triplet and higher-order multiple pregnan-
cies increased by more than 400 percent (1). In the majority
of developed countries, 30-50% of all twin pregnancies occur
as a result of infertility treatment (2). In the United States,
multiple pregnancies were reported to occur in 35.4% of in
vitro fertilization cycles, which is more than ten times the
natural multiple pregnancy rate (3).
The majority of perinatal morbidities associated with mul-
tiple gestations are related to preterm delivery. Gestational
age at delivery and birth weight are the two most impor-
tant factors that affect perinatal, neonatal, and infant mor-
bidity and mortality (4). In addition to the morbidity and
mortality attributable to preterm delivery, fetuses in multi-
ple gestations are vulnerable to a variety of complications,
such as malformations and twin-to-twin transfusion syn-
drome. Maternal complications such as preeclampsia, gesta-
tional diabetes, postpartum hemorrhage, and maternal death
are also increased in multiple gestations, and these risks are
further increased in triplet or higher-order multiple preg-
nancies (5).
Multifetal pregnancy reduction (MFPR) is a procedure
that reduces higher-order pregnancies, which improves peri-
natal outcomes. Multifetal pregnancy reduction in triplet
and higher-order multiple pregnancies significantly reduces
the risks of prematurity and a low birth weight, and may
also be associated with a reduction in overall pregnancy loss
and obstetric complications (6-8). Moreover, no significant
differences were found in mean gestational age at birth, birth
weight, and perinatal mortality rates between reduced and
non-reduced twins (9). A recent meta-analysis concluded
that multifetal pregnancy reduction to twins, compared with
expectant management, seems to be an effective treatment
option for women with a triplet pregnancy (10). These results
suggest that MFPR of higher-order pregnancies to twins is
a medically justifiable procedure.
Since the MFPR was first introduced in the mid-eighties
(11), several modifications of methods have been developed.
Various options are available in regard to the route of ap-
proach, the timing of procedure, and the use of embryotoxic
agents such as potassium chloride (KCl). However, contro-
versy still exists regarding which method is better than the
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Pregnancy Outcomes of Different Methods for Multifetal Pregnancy
Reduction: A Comparative Study
The purpose of this study was to evaluate the outcomes of various methods of multi-
fetal pregnancy reduction (MFPR) and to determine which method produces better
outcomes. One hundred and forty-eight patients with multiple pregnancies resulting
from assisted reproduction programs and underwent MFPR were included. Accord-
ing to the use of potassium chloride (KCl), patients were divided into ‘KCl’, and ‘non-
KCl’ groups, and based on gestational age at the time of procedures, patients were
divided into ‘Early’ (before 8 weeks of gestation) and ‘Late’ (at 8 weeks or later)
groups. Firstly, to clarify the effect of each component of MFPR procedure, data
were analyzed between ‘KCl’ and ‘non-KCl’ groups, and between ‘Early’ and ‘Late’
groups with adjustments. Secondly, comparison between ‘Early, non-KCl’ and ‘Late,
KCl’ groups was performed to evaluate the combinative effect of both components.
Non-KCl groups showed a significantly higher take-home-baby rate, and lower risk
of extreme prematurity and preterm premature rupture of membranes (PPROM)
than KCl groups. Early groups showed a lower immediate loss rate than Late groups.
As compared with ‘Late, KCl’ group, ‘Early, non-KCl’ group was superior in terms
of immediate loss, pregnancy loss, take-home-baby, and PPROM rates. Our data
suggest that the ‘early, non-KCl’ method may be a better option for MFPR.
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others (12-15). We retrospectively analyzed different meth-
ods for MFPR to evaluate the outcomes of procedure, and to
determine which produces the better outcomes.
MATERIALS AND METHODS
Patients
One hundred and forty-eight patients with multiple preg-
nancies, resulting from in vitro fertilization-embryo transfer
or intrauterine insemination, and underwent MFPR between
January 2000 and December 2005 were included in this
study. We retrospectively reviewed medical records of the
patients. One hundred and one gestations were triplets (68.2
%), 33 were quadruplets (22.3%), 11 were quintuplets or
higher-order pregnancies (7.5%), and 3 were twins (2.0%).
All cases of MFPR were performed for the purpose of reduc-
ing the fetal number. Patients were counseled regarding the
risk of miscarriage and preterm delivery in multiple preg-
nancies and offered the option of MFPR. If the patients chose
the option, possible risks of the procedure were explained
and informed consents were obtained. This study was approv-
ed by our institutional review board.
MFPR procedure
All MFPR procedures were performed at 6+0 to 15+6
weeks of gestational age and were performed by experienced
operators. Before procedure, an ultrasound scan was perform-
ed using a 5.0 MHz transducer (Panavista-VA GM-2600A,
Matsushita, Japan) to determine the number, locations, and
sizes of fetuses and gestational sacs. Fetal heart beats were
confirmed in each fetus before starting the procedure. After
patients had been placed into the lithotomy position, the
vagina was prepared with 10% povidone iodine and then
thoroughly rinsed with sterile saline solution. Antibiotic
prophylaxis with intravenous injection of cefazolin 2.0 g was
administered one hour prior to each procedure. Under sono-
graphic guidance with on-screen guideline, the selected fetus
was approached transvaginally with a 19-gauge needle. Most
easily accessible fetuses were selected for embryo reduction.
Alternatively, embryos with a smaller fetal or sac size were
selected.
Cardiac puncture and aspiration of amniotic fluid were
performed, and the aspiration of fetus was done if possible.
Suction was applied using a 50 mL syringe, which resulted
in complete or partial aspiration of the embryo and amniotic
fluid. An intracardiac (or intrathoracic) injection of 2 mEq/
mL of KCl was performed at the operator’s discretion. After
ensuring that the fetus concerned had been completely aspi-
rated, or if not, that no fetal heart beat occurred over one
minute, the needle was withdrawn. The above procedure
was repeated for other gestational sacs in cases of quadruplet
or higher-order pregnancies. Follow-up ultrasound exami-
nation was carried out after one week. All patients under-
went subsequent prenatal routine follow-up.
Study design
According to the use of KCl, patients were divided into
‘KCl’ and ‘non-KCl’ groups, and based on gestational age at
the time of procedures, patients were divided into ‘Early’ and
‘Late’ groups. In the ‘Early’ groups, reduction was perform-
ed before 8 weeks of gestation, and in the ‘Late’ groups, at 8
weeks or later. Finally, in combination, subjects were divided
into four groups according to the use of KCl and gestational
age at procedure, i.e., the ‘Early, non-KCl’ (n=60), ‘Late, non-
KCl’ (n=12), ‘Early, KCl’ (n=21), and ‘Late, KCl’ groups
(n=55). The choice of cut-offs used to define ‘Early’ and ‘Late’
groups was arbitrary and based on the fact that, in the ges-
tational ages earlier than 8 weeks, it is not difficult to aspi-
rate all or most of the fetal parts, since the size of fetuses are
relatively small (16). Firstly, to clarify the effect of each com-
ponent of MFPR procedure, data were analyzed between
‘KCl’ and ‘non-KCl’ groups, and between ‘Early’ and ‘Late’
groups with adjustments. Secondly, comparison between
the four groups was performed to evaluate the combinative
effect of both components. 
Pregnancy outcomes
The primary outcomes were the results of MFPR, i.e.,
immediate loss rate, pregnancy loss rate, and take-home-
baby rate. Immediate loss was defined as fetal loss within 4
weeks of the procedure and such cases were considered as pro-
cedure-related losses. Pregnancy loss was defined as fetal loss
up to 24 weeks’ gestation, and take-home-baby rate as live
birth rate per patient. The secondary outcomes were obstet-
ric outcomes, i.e., the gestational ages, birth weight of babies
at delivery, and complications of fetuses and mothers. Extreme
prematurity was defined as preterm delivery before 28 weeks’
gestation. Preterm premature rupture of membranes (PP-
ROM) was defined as the rupture of amniotic membrane
without labor pain during the preterm period. 
Statistical analysis
Statistical analysis was performed using analysis of vari-
ance (ANOVA) and the Student’s t-test for continuous vari-
ables, whereas chi-square and Fisher’s exact tests were used
for categorical variables, as appropriate. Probability values
were adjusted for gestational ages when analyzing differences
between KCl and non-KCl groups, and for KCl use when
analyzing differences between Early and Late groups. Anal-
ysis of covariance (ANCOVA) or Mantel-Haenszel chi-square
test was used for adjustment. The statistical software pack-
age SPSS version 12.0 (SPSS Inc., Chicago, IL, U.S.A.) wasOutcomes of Multifetal Pregnancy Reduction 113
used for statistical analysis, and results were considered sta-
tistically significant at p<0.05.
RESULTS
The mean age of the subjects was 30.6±2.9 yr. Eighty-
one MFPRs were performed before 8 weeks’ gestational age
(54.7%) and 67 procedures were performed at 8 weeks or
later (45.3%). In 76 patients, KCl was used as the embryo
toxic agent (51.4%) and not used in the other 72 patients
(48.6%). Maternal ages and characteristics of the MFPR pro-
cedures such as starting number of fetuses, finishing number
of fetuses, and the number of procedures required to complete
the procedure were not different among the four groups. Ges-
tational ages at the times of procedure were different between
the groups (Table 1).
Mean gestational ages at delivery and birth weights were
not different between KCl and non-KCl groups and between
Early and Late groups. As compared with KCl groups, non-
KCl groups showed a significantly higher take-home-baby
rate (86.1% vs. 69.7%, p=0.045). Immediate loss and preg-
nancy loss rates were lower in non-KCl groups than in KCl
groups, but the differences were not statistically significant
(5.6% vs. 10.5% and 12.5% vs. 23.7%, respectively). A sig-
nificant difference was found between Early and Late groups
in terms of immediate loss rates (2.5% vs. 14.9%, p=0.019).
Early groups showed a lower pregnancy loss rate and a higher
take-home-baby rate compared with Late groups, but the
differences were not statistically significant (12.3% vs. 25.4%
and 81.5% vs. 73.1%, respectively) (Table 2).
Fetal and maternal complications, such as fetal growth
restrictions, discordant twins, congenital anomalies, gesta-
tional hypertension, and cervical incompetence were not dif-
ferent between KCl and non-KCl groups or between Early
and Late groups. Extreme prematurity rates were significant-
Early, non-KCl
group (n=60)
Late, non-KCl
group (n=12)
Early, KCl
group (n=21)
Late, KCl group
(n=55)
p*
Maternal age (yr) 30.6±2.6 31.2±2.5 30.5±2.8 30.7±2.9 NS
Gestational age at procedure (wks) 7.3±0.4 8.8±1.3 7.6±0.3 9.1±1.2 <0.001
Starting number of fetuses 3.3±0.6 3.2±0.4 3.8±0.9 3.3±0.8 NS
Finishing number of fetuses 2.0±0.1 1.8±0.4 2.0±0 1.9±0.3 NS
Number of trials 1.1±0.3 1.0±0 1.2±0.4 1.2±0.5 NS
Table 1. Comparison of the maternal ages and characteristics of multifetal pregnancy reduction procedures between groups
All values are means±SD. *by ANOVA.
NS, not significant. 
KCl groups
(n=76)
Early groups 
(n=81)
Non-KCl groups
(n=72)
p
� Late groups 
(n=67)
p
�
Gestational age at delivery (wks)* 35.5±3.8 35.9±2.0 NS 35.4±3.0 36.1±3.0 NS
Birth weight (g)* 2,297.3±648.1 2,314.0±396.6 NS 2,247.3±493.8 2,389.1±579.2 NS
Immediate loss rate (%) 10.5 (8/76) 5.6 (4/72) NS 2.5 (2/81) 14.9 (10/67) 0.019
Pregnancy loss rate (%) 23.7 (18/76) 12.5 (9/72) NS 12.3 (10/81) 25.4 (17/67) NS
Take-home-baby rate (%) 69.7 (53/76) 86.1 (62/72) 0.045 81.5 (66/81) 73.1 (49/67) NS
Table 2. Pregnancy outcomes according to the different methods of multifetal pregnancy reduction
*Values are means±SD; 
� Adjusted for gestational ages at procedure; 
� Adjusted for the use of KCl.
NS, not significant. 
KCl groups
(n=76)
Early groups 
(n=81)
Non-KCl groups
(n=72)
p*
Late groups 
(n=67)
p
�
Extreme prematurity (%) 8.6 (5/58) 1.6 (1/64) 0.020 6.9 (5/72) 2.0 (1/50) NS
PPROM (%) 27.6 (21/76) 9.7 (7/72) 0.019 14.8 (12/81) 23.9 (16/67) NS
Fetal growth restriction (%) 10.3 (6/58) 9.5 (6/63) NS 9.9 (7/71) 10.0 (5/50) NS
Discordant twin (%) 5.2 (3/58) 4.8 (3/63) NS 5.6 (4/71) 4.0 (2/50) NS
Congenital anomaly (%) 0 (0/58) 4.8 (3/63) NS 4.2 (3/71) 0 (0/50) NS
Gestational hypertension (%) 9.2 (7/76) 2.8 (2/72) NS 2.5 (2/79) 10.4 (7/67) NS
Cervical incompetence (%) 5.3 (4/76) 5.6 (4/72) NS 4.9 (4/81) 6.0 (4/67) NS
Table 3. Fetal and maternal complications according to the different methods of multifetal pregnancy reduction
*Adjusted for gestational ages at procedure; 
� Adjusted for the use of KCl.
PPROM, preterm premature rupture of membranes; NS, not significant. 114 J.R. Lee, S.-Y. Ku, B.C. Jee, et al.
ly higher in KCl groups than in non-KCl groups (8.6% vs.
1.6%, p=0.020). PPROM occurred significantly more fre-
quently in KCl groups than in non-KCl groups (27.6% vs.
9.7%, p=0.019) (Table 3). 
The ‘Early, non-KCl’ group showed a significantly lower
immediate loss rate, pregnancy loss rate, and PPROM rate as
compared with the ‘Late, KCl’ group (3.3% vs. 14.5%, p=
0.033; 11.7% vs. 27.3%, p=0.034; 10.0% vs. 27.3%, p=0.017,
respectively). The take-home-baby rate was significantly high-
er in the ‘Early, non-KCl’ group than in the ‘Late, KCl’ group
(86.7% vs. 70.9%, p=0.038) (Table 4).
DISCUSSION
Several methods of MFPR are available based on different
combinations of three components, i.e., the use of embry-
otoxic agent, the timing of procedure, and the route of ap-
proach. However, it is difficult to determine which one is a
better option because prospective randomized studies or
simultaneous comparisons among these variable methods
are difficult to perform. In particular, no randomized con-
trolled trial has been conducted (17), and few comparative
studies have been conducted to compare the effects of differ-
ent factors on outcomes. The present study is a retrospective
comparative study of different modalities comprised of two
components of the MFPR procedure, i.e., the use of an embry-
otoxic agent, and the timing of procedure. To our knowledge,
this is the first study to evaluate the impact of those two
components simultaneously.
Potassium chloride is widely used for MFPR, but the safe-
ty and efficacy of this agent are debatable. Cases of anence-
phaly and limb amputation have been reported, and total
pregnancy loss may be resulted if the KCl solution acciden-
tally reaches the amniotic fluid of remaining fetuses (18). It
has been suggested that the development of an inflammato-
ry response to the resorbing dead feto-placental tissue with
subsequent release of cytokines and stimulation of prosta-
glandins is a cause of pregnancy loss, preterm delivery, and
other complications following MFPR (19-21). All procedures
in those studies were performed by KCl injection. Based on
those previous findings and our results, we suggest that the
use of KCl for MFPR may cause or aggravate the inflamma-
tory process and induce PPROM and preterm birth.
The reason for the higher PPROM rate for KCl groups in
the present study is not clear. However, several reports have
demonstrated that PPROM is associated with matrix degrad-
ing enzymes, such as, plasminogen activators (PAs) and matrix
metalloproteinases (MMPs) (22-24). Moreover, in animal
studies, investigators found that KCl can induce a release of
tissue plasminogen activator in the hypothalamo-neurohy-
pophysial system (25) and an upregulation in MMP-9 activ-
ity in the retina, which promote retinal damage (26). Al-
though no study has been conducted on the roles of KCl in
relation to matrix degrading enzyme activity in the intrauter-
ine system, we hypothesize that KCl can cause PPROM by
inducing matrix degrading enzymes in the uterus after MFPR.
Optimal MFPR timing remains controversial. There have
been studies that suggested that fetal reduction should be
delayed until the late first trimester, based on the expecta-
tion of a natural reduction of fetus and a detection of anoma-
lies (27, 28). However, studies that have focused on loss rates
per gestational sac or embryo, not per patient, observed that
the rates of spontaneous fetal demise in multiple gestations
during early pregnancy were much lower than those report-
ed by other studies that did not consider this condition (29-
31). Moreover, reported rates of malformation after MFPR
are lower than expected rates, which is probably due to the
tendency to selectively reduce embryos with a higher risk of
congenital malformation (12). Several studies reported that
MFPR during early gestation, at 7-8 weeks, without KCl
injection showed superior results to that performed later
(13, 16). In the present study, better outcomes were observed
in the Early groups, and we confirm these previous study
results.
Our data show that ‘early, non-KCl’ is the best of the dif-
ferent MFPR methods. This is thought to have both advan-
tages of early MFPR and that of non-KCl MFPR. Perform-
ing MFPR in earlier gestational age without KCl injection
makes the procedure easier because the targeted fetus is rel-
atively small and easily aspirated. If the procedure is per-
formed in later gestation, the relatively large fetus cannot be
Early, non-KCl
group (n=60)
Late, non-KCl
group (n=12)
Early, KCl group
(n=21)
Late, KCl group
(n=55)
p
� p
�
Gestational age at delivery (wks)* 36.0±1.9 35.5±2.4 33.9±4.6 36.2±3.1 NS NS
Birth weight (g)* 2,323.5±399.1 2,262.2±401.3 2,040.0±659.2 2,419.2±614.3 NS NS
Immediate loss rate (%) 3.3 (2/60) 16.7 (2/12) 0 (0/21) 14.5 (8/55) 0.037 0.033
Pregnancy loss rate (%) 11.7 (7/60) 16.7 (2/12) 14.3 (3/21) 27.3 (15/55) NS 0.034
Take-home-baby rate (%) 86.7 (52/60) 83.3 (10/12) 66.7 (14/21) 70.9 (39/55) NS 0.038
Extreme prematurity (%) 1.9 (1/53) 0 (0/10) 22.2 (4/18) 2.5 (1/40) 0.016 NS
PPROM (%) 10.0 (6/60) 8.3 (1/12) 28.6 (6/21) 27.3 (15/55) 0.047 0.017
Table 4. Comparison of pregnancy outcomes and complications among the four groups
*Values are means±SD; 
� Among the four groups; 
� Between the ‘Early, non-KCl’ and ‘Late, KCl’ groups.
NS, not significant. easily terminated. The early, non-KCl method is also easier
and faster than the other methods and is probably related to
fewer procedure-related complications. The significantly
lower immediate loss rate in the ‘Early, non-KCl’ group in
our data supports this suggestion. Another advantage of the
early method is that it avoids the use of KCl. Potassium chlo-
ride is more needed as gestational age increases because larger
fetuses cannot be easily terminated by aspiration without KCl
injection. As we have discussed earlier, using KCl is not a
safe way to perform MFPR, and thus, the use of KCl should
be avoided. Early MFPR favors this approach. The early,
non-KCl method has benefits of both early and non-using
KCl procedure, and thus it could be the best among the
four methods investigated.
In the present study, all procedures were performed via
the transvaginal route. Several studies have been conducted
on different routes of approach, and shown controversial
results (12, 15, 32). Experience and skill are also important
factors in addition to the route of approach. Like any other
procedures, MFPR has a learning curve, and thus outcomes
improve with the number of cases. In a collaborative study
of 3,513 cases from 11 centers, Evans et al. found the out-
comes improved considerably with increasing experience
(33). Therefore, if poor initial outcomes are inevitable due
to the learning curve, simpler methods should be adopted.
Reproductive physicians are more comfortable with transvagi-
nal MFPR because the procedure is similar to ovum aspira-
tion under transvaginal ultrasonographic guidance. Thus,
transvaginal MFPR requires fewer technical considerations
than transabdominal MFPR. Moreover, not every center per-
forms several hundreds of MFPR procedures as in the large
centers included in the previous studies. As cases of high-
order multiple pregnancies become less frequent, the num-
ber of cases requiring MFPR will also decrease. In this situ-
ation, each center must choose the method that best fits its
own situation. Transvaginal MFPR could be a better option
for centers that perform relatively few procedures and have
relatively less experiences. In a collaborative study involving
more than 1,000 cases, Evans et al. (32) observed that trans-
abdominal MFPR was more associated with a poor outcome
than transcervical or transvaginal MFPR earlier in the series,
which also support our suggestion.
Limitations of the present study should be mentioned.
First, this is an observational study and not a randomized
controlled trial; hence there may be confounding variables
that might have influenced the results. However, the simi-
larity between the groups in clinical characteristics such as
maternal age, starting number of fetuses, finishing number
of fetuses, and number of trials supported that selection bias
would be minimal. Second, regarding sample sizes, 250 pati-
ents in each group achieve 80% power at a 5% significance
level when the difference of take-home-baby rate is 10%.
Sample size calculations with other proportional variables
showed similar results. In the present study, there are several
proportional data that showed a nonsignificant trend of about
10% difference. We could not rule out the possibility that the
nonsignificant differences seen in those data could be attribut-
ed to a type II error. Further studies in a larger scale will be
necessary.
In conclusion, we suggest that the early transvaginal non-
KCl method is a better option for MFPR. We believe that it
should be considered as the first choice modality in the major-
ity of centers. 
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